Agios Pharmaceuticals (AGIO) Competitors $37.34 +0.92 (+2.53%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGIO vs. GRFS, RYTM, ABVX, CYTK, LEGN, AXSM, NUVL, RNA, MRUS, and CRSPShould you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), Cytokinetics (CYTK), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Avidity Biosciences (RNA), Merus (MRUS), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Agios Pharmaceuticals vs. Its Competitors Grifols Rhythm Pharmaceuticals Abivax Cytokinetics Legend Biotech Axsome Therapeutics Nuvalent Avidity Biosciences Merus CRISPR Therapeutics Grifols (NASDAQ:GRFS) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation. Does the media refer more to GRFS or AGIO? In the previous week, Agios Pharmaceuticals had 5 more articles in the media than Grifols. MarketBeat recorded 10 mentions for Agios Pharmaceuticals and 5 mentions for Grifols. Grifols' average media sentiment score of 0.55 beat Agios Pharmaceuticals' score of 0.43 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is GRFS or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,590.42% compared to Grifols' net margin of 0.00%. Grifols' return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Agios Pharmaceuticals 1,590.42%-3.49%-3.23% Which has more risk & volatility, GRFS or AGIO? Grifols has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Which has higher valuation & earnings, GRFS or AGIO? Agios Pharmaceuticals has lower revenue, but higher earnings than Grifols. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.45B0.90$169.80M$1.178.36Agios Pharmaceuticals$40.88M53.06$673.72M$11.003.39 Do analysts rate GRFS or AGIO? Grifols presently has a consensus price target of $10.30, indicating a potential upside of 5.32%. Agios Pharmaceuticals has a consensus price target of $56.00, indicating a potential upside of 50.02%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryAgios Pharmaceuticals beats Grifols on 9 of the 15 factors compared between the two stocks. Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGIO vs. The Competition Export to ExcelMetricAgios PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.17B$3.13B$5.79B$10.36BDividend YieldN/A2.37%5.86%4.62%P/E Ratio3.4021.3376.8626.91Price / Sales53.06254.11450.9189.68Price / CashN/A45.4837.2260.63Price / Book1.389.6313.756.37Net Income$673.72M-$53.02M$3.29B$271.38M7 Day Performance2.27%0.89%0.53%2.11%1 Month Performance-0.32%5.38%4.89%7.56%1 Year Performance-18.03%11.82%83.74%31.10% Agios Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGIOAgios Pharmaceuticals4.3358 of 5 stars$37.33+2.5%$56.00+50.0%-20.3%$2.17B$40.88M3.40390Gap UpGRFSGrifols3.9524 of 5 stars$9.63-2.5%$10.30+7.0%+9.6%$6.79B$7.81B8.2323,822News CoverageRYTMRhythm Pharmaceuticals3.289 of 5 stars$96.03-0.2%$101.57+5.8%+80.7%$6.39B$156.29M-31.90140Positive NewsABVXAbivax2.6887 of 5 stars$85.87+2.2%$99.43+15.8%+613.7%$6.35BN/A0.0061Positive NewsShort Interest ↑CYTKCytokinetics4.3751 of 5 stars$49.44-3.3%$75.38+52.5%-15.3%$6.12B$18.47M-9.69250Insider TradeLEGNLegend Biotech3.2306 of 5 stars$33.88+2.3%$74.22+119.1%-32.6%$6.11B$627.24M-38.502,609Positive NewsAXSMAxsome Therapeutics4.8994 of 5 stars$116.78-1.4%$177.86+52.3%+28.2%$5.91B$495.03M-23.03380News CoverageInsider TradeAnalyst RevisionNUVLNuvalent3.1618 of 5 stars$79.37-1.4%$120.91+52.3%-24.9%$5.80BN/A-16.2040Insider TradeRNAAvidity Biosciences2.1477 of 5 stars$40.22-10.1%$68.94+71.4%-5.0%$5.76B$10.90M-11.30190Analyst ForecastMRUSMerus3.0579 of 5 stars$68.09-2.1%$88.75+30.3%+36.1%$5.26B$36.13M-12.3837Analyst ForecastCRSPCRISPR Therapeutics3.4 of 5 stars$57.84+2.8%$71.60+23.8%+18.4%$5.12B$37.31M-10.65460News CoverageAnalyst Forecast Related Companies and Tools Related Companies Grifols Alternatives Rhythm Pharmaceuticals Alternatives Abivax Alternatives Cytokinetics Alternatives Legend Biotech Alternatives Axsome Therapeutics Alternatives Nuvalent Alternatives Avidity Biosciences Alternatives Merus Alternatives CRISPR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGIO) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThis Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGIO Stock Alerts